Substrate
health

Japan Passes Bill Raising Co-Payments for Select Prescription Drugs

Japan's Upper House approved legislation on Friday to increase patient co-payments for roughly 1,100 prescription medicines that have ingredients and effects similar to over-the-counter drugs. The same bill also expands public health insurance coverage to include all childbirth-related costs.

The Japan Times
1 source·May 29, 3:58 AM·1m read
Japan Passes Bill Raising Co-Payments for Select Prescription DrugsThe Japan Times
Audio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.

Japan's Upper House passed legislation on Friday that will raise co-payments for certain prescription medicines starting in March 2027. The measure targets about 1,100 drugs whose ingredients and effects are similar to over-the-counter products. The bill reforms the national healthcare insurance system and aims to limit future increases in insurance premiums paid by the working population.

It passed by majority vote during the chamber's plenary session.

The legislation also places all costs associated with childbirth under public health insurance. Standard deliveries are currently excluded from coverage. Women who give birth now receive a one-time allowance of ¥500,000 ($3,130) per child. The bill states that actual hospital delivery costs vary, and the fixed payment is often insufficient to cover expenses.

The health ministry plans to implement the higher co-payments for the identified medicines in March 2027.

Transparency

Confidence75%

Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.

Story details

Related Stories

Phase 3 Trial Finds Daraxonrasib Extends Median Survival to 13 Months vs 7 Months for Chemotherapy in Second-Line Pancreatic CancerNew Scientist
health1 hr ago

Phase 3 Trial Finds Daraxonrasib Extends Median Survival to 13 Months vs 7 Months for Chemotherapy in Second-Line Pancreatic Cancer

A 500-person study found the once-daily pill halted or reversed tumor progression in nearly one-third of patients versus 10 percent on chemotherapy. Median survival rose from less than seven months to roughly 13 months.

Cbc
New Scientist
2 sources
Bundibugyo Ebola Strain Shows High Survival Rate in DRC; Suspected Cases Reported in Brazil and Italynypost.com
health11 hrs agoFraming65Framing risk65/100Rewrite inherits heavy consensus framing of an alarming, out-of-control outbreak despite data showing unusually high survival rate for this strain.Click to jump to full framing analysis

Bundibugyo Ebola Strain Shows High Survival Rate in DRC; Suspected Cases Reported in Brazil and Italy

Four nurses and one laboratory worker have recovered from Ebola caused by the Bundibugyo strain in the Democratic Republic of Congo. Suspected cases linked to travel from affected countries are under investigation in Brazil and Italy.

Cnn
AllAfrica
dimsumdaily.hk
3 sources
Ebola Outbreak in Eastern Congo Reaches 906 Suspected Casescitizen.co.za
health2 days agoFraming68Framing risk68/100Rewrite inherits heavy consensus framing from sources, centering anonymous MSF warnings, predictive gloom, and lede misdirection around Tedros' visit over the substantive outbreak facts.Click to jump to full framing analysis

Ebola Outbreak in Eastern Congo Reaches 906 Suspected Cases

WHO Director-General Tedros Adhanom Ghebreyesus arrived in Bunia on May 30 to assess the response to a Bundibugyo virus outbreak that has killed 223 people. Officials reported cases spreading to North Kivu and South Kivu, while Uganda confirmed nine infections.

Abc News
Associated Press
cbsnews.com
content.api.nytimes.com
4 sources